Drug profile · INN
lusutrombopag
MULPLEO (PREVIOUSLY LUSUTROMBOPAG SHIONOGI)
lusutrombopag (MULPLEO (PREVIOUSLY LUSUTROMBOPAG SHIONOGI)) is a thrombopoietin receptor agonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — lusutrombopag
- US status
- approved
- Class
- Blood and blood forming organs (B02)
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
lusutrombopag (MULPLEO (PREVIOUSLY LUSUTROMBOPAG SHIONOGI)) is a thrombopoietin receptor agonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Thrombopoietin receptor agonist
Primary target: Thrombopoietin receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is lusutrombopag?
lusutrombopag (MULPLEO (PREVIOUSLY LUSUTROMBOPAG SHIONOGI)) is a thrombopoietin receptor agonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for lusutrombopag?
MULPLEO (PREVIOUSLY LUSUTROMBOPAG SHIONOGI) is a marketed brand name for lusutrombopag. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lusutrombopag?
lusutrombopag has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.